Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Says Chinese Patent Office to Grant Patent on RNAi Molecules

Premium

Alnylam Pharmaceuticals this week announced that it has been notified that the Chinese patent office intends to grant a patent, assigned to the Max Plank Society and exclusively licensed to Alnylam, covering siRNAs.

According to the company, the patent application — No. 01820900.9 — is part of the so-called Tuschl II family of intellectual property and covers the compositions, methods, uses, and systems of double-stranded RNAs having key structural elements including a length of between 19 and 25 nucleotides; one or more 3' overhangs at the ends of the molecule; and chemical modifications on the 3' end.

The application also claims the use of such molecules to modulate gene function in mammals or pathogen-derived genes in vitro and in vivo, Alnylam said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.